Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
1(17%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
17%
Ph phase_3
1
17%
Ph phase_2
3
50%

Phase Distribution

0

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
1(20.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Not yet recruiting3
Recruiting1
Completed1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 31 (20.0%)
N/A1 (20.0%)

Trials by Status

not_yet_recruiting350%
recruiting117%
completed117%
enrolling_by_invitation117%

Recent Activity

1 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

NCT07254858
recruiting

Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

NCT07054086
not_yet_recruitingphase_3

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

NCT06957938
not_yet_recruitingphase_2

Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC

NCT06916117
enrolling_by_invitationnot_applicable

CNCMT：a Multi-center, Prospective, Single-arm Study

NCT06714084
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07254858Phase 2

Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

Not Yet Recruiting
NCT07054086

Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Recruiting
NCT06957938Phase 3

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

Not Yet Recruiting
NCT06916117Phase 2

Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC

Not Yet Recruiting
NCT06714084Not Applicable

CNCMT：a Multi-center, Prospective, Single-arm Study

Enrolling By Invitation
NCT02249013Phase 2

Short-course HIPEC in Advanced Epithelial Ovarian Cancer

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6